The U.S. Food and Drug Administration approved a new drug combination on November 13, 2026, for adults with muscle-invasive bladder cancer who cannot receive or choose to decline traditional cisplatin-based chemotherapy. According to the U.S. Food and Drug Administration, the approved treatment pairs AstraZeneca's immunotherapy durvalumab (Imfinzi) with the targeted medicine enfortumab vedotin-ejfv (Padcev) before surgical removal of the bladder, followed by durvalumab alone after surgery. Clinical trial results showed this approach cut the risk of death by 42% and reduced the risk of cancer recurrence or progression by 49% compared to surgery alone.

In the United States, approximately 16,000 patients receive treatment for muscle-invasive bladder cancer in 2026, according to AstraZeneca. Roughly one in four bladder cancer diagnoses involves a tumor that has grown into the muscle wall of the bladder without spreading to distant organs.

While standard treatment often pairs bladder removal surgery—known as a radical cystectomy—with pre-surgical cisplatin chemotherapy, up to 50% of patients cannot safely take cisplatin due to reduced kidney function or other health conditions. Historically, patients who could not take cisplatin or declined the drug relied on surgery alone, facing high rates of the cancer returning.

Survival Outcomes in the VOLGA Trial

The federal approval relies on data from the Phase 3 VOLGA trial, which enrolled 695 patients with muscle-invasive bladder cancer who were candidates for bladder removal surgery and were either ineligible for or refused cisplatin-based chemotherapy. Researchers randomly assigned patients into three equal groups to evaluate the durvalumab and enfortumab vedotin combination against surgery alone, alongside a third investigational treatment arm.

The primary findings were presented on October 24 during the 2026 European Society for Medical Oncology Congress in Madrid, Spain, and published simultaneously in The New England Journal of Medicine, according to the American Journal of Managed Care.

Reports frame the trial's survival benefits from both relative and absolute statistical angles. According to the U.S. Food and Drug Administration, the trial evaluated event-free survival—measuring the time patients live without their cancer progressing, returning, preventing them from undergoing surgery, or resulting in death—and recorded a hazard ratio of 0.51, while overall survival showed a hazard ratio of 0.58. AstraZeneca translates these figures as a 49% reduction in the risk of disease recurrence, progression, not undergoing surgery, or death, and a 42% reduction in the risk of death compared to surgery alone.

Meanwhile, Medscape reports the two-year milestone figures, noting that 63.5% of patients receiving the drug combination remained event-free at 24 months compared to 45.1% of those who had surgery alone, while 24-month overall survival reached 78.4% with the drug regimen versus 69.4% for surgery alone.

Looking at median timelines, patients who underwent surgery alone experienced a median event-free survival of 12.1 months, whereas those receiving the drug regimen had not yet reached a median threshold during the analysis period, meaning more than half remained free of those complications. Median overall survival had not yet been reached in either treatment group at the time of the interim analysis.

"Patients with muscle-invasive bladder cancer require life-changing bladder removal surgery. Despite this, the cancer returns in about half of patients," said Thomas Powles, chair and professor of Genitourinary Oncology at Barts Cancer Institute in London, in a statement reported by the American Journal of Managed Care.

"A new regimen of perioperative durvalumab combined with enfortumab vedotin before surgery reduced the risk of death by 42%, with a manageable safety profile. These practice-changing results support this approach as a patient centric, potential new standard of care in this setting."

How the New Regimen Fits Into Bladder Cancer Care

The treatment options for muscle-invasive bladder cancer have shifted substantially over the past two years. For patients healthy enough to tolerate standard chemotherapy, the NIAGARA trial previously established durvalumab combined with cisplatin-based chemotherapy as a standard approach. For those who cannot take cisplatin, the targeted antibody-drug conjugate enfortumab vedotin has increasingly been paired with immunotherapy.

In November 2025, the FDA approved enfortumab vedotin combined with pembrolizumab (Keytruda) for cisplatin-ineligible patients, expanding that approval to cisplatin-eligible patients in July 2026.

In that pembrolizumab-based schedule, patients receive enfortumab vedotin for three cycles before surgery and continue taking it for six cycles after surgery, with post-surgical therapy lasting 42 weeks in total.

The newly approved VOLGA regimen structures treatment differently by limiting enfortumab vedotin exclusively to the pre-surgical phase. Jonathan E. Rosenberg, Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center and a member of the VOLGA Steering Committee, noted the importance of this schedule in a statement from AstraZeneca. "This approval brings the first perioperative immunotherapy regimen where enfortumab vedotin is administered only in the neoadjuvant setting to patients with muscle-invasive bladder cancer who are not candidates for cisplatin-based chemotherapy," Rosenberg said.

Side Effects and Safety Considerations

While adding pre- and post-surgical medication improves survival odds, it also brings a higher rate of side effects than surgery alone. According to Oncology Nursing News, severe adverse events—classified as Grade 3 or higher from any cause—occurred in 71.1% of patients treated with the durvalumab and enfortumab vedotin regimen, compared to 50.2% of patients who underwent surgery alone.

According to the U.S. Food and Drug Administration, more than 20% of patients taking the combination experienced side effects or laboratory changes including elevated liver and pancreatic enzymes, anemia, skin rash, itching, elevated creatinine levels, urinary tract infections, fatigue, diarrhea, constipation, reduced appetite, altered taste, nausea, nerve pain (peripheral neuropathy), muscle or bone pain, hair loss, and drops in white blood cell, calcium, or sodium counts. Prescribing guidelines also carry warnings for immune-system reactions, infusion reactions, stem cell transplant complications, and risks to unborn fetuses.

Frequently Asked Questions

Who qualifies for this newly approved bladder cancer treatment?

While some medical headlines use the shorthand "cisplatin-ineligible" to describe the patient group, the official U.S. Food and Drug Administration approval covers two distinct groups of adults with muscle-invasive bladder cancer: those who are medically unable to take cisplatin-based chemotherapy due to issues like kidney impairment or other health conditions, and patients who are medically eligible for cisplatin but choose to refuse it.

What is the exact dosing schedule before and after surgery?

For adults weighing 30 kilograms (about 66 pounds) or more, treatment before bladder removal surgery consists of 1,500 mg of durvalumab given every three weeks alongside 1.25 mg/kg of enfortumab vedotin given on days one and eight of each three-week cycle, lasting for three cycles. Following surgery, patients receive 1,500 mg of durvalumab alone every four weeks for up to nine cycles. Patients weighing under 30 kilograms receive weight-adjusted durvalumab doses of 20 mg/kg on the same schedule.

Does this trial prove the regimen is better than other drug combinations?

No. Because the VOLGA trial compared the durvalumab and enfortumab vedotin combination directly against radical cystectomy alone, the findings establish its benefit over surgery by itself. The trial was not designed as a head-to-head comparison against other systemic therapies, such as the pembrolizumab and enfortumab vedotin regimen.

Sources